At the JPMorgan Healthcare Conference, Moderna reports that it will have sold around $6.7 billion worth of products in 2023 and increased its Covid-19 market share in the USA from 37% in 2022 to 48% in 2023.

The biotech company reiterates its objectives of product sales of around $4 billion in 2024, a return to growth in 2025 and break-even in 2026 thanks to disciplined product launches and investments.

"We are preparing for the launch of Moderna's second product, our RSV vaccine", emphasizes CEO Stéphane Bancel, who expects "an exciting 2024, with multiple milestones in our nine late-stage programs".

Copyright (c) 2024 CercleFinance.com. All rights reserved.